On October 4, 2023 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, reported a poster presentation at the upcoming 2023 AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) hosted by the American Association for Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023 (Press release, Adicet Bio, OCT 4, 2023, View Source [SID1234635664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation is as follows:

Abstract Title: Characterization of Allogeneic CAR γδ1 T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA (Prostate-Specific Membrane Antigen)

Poster Number: C117

Presenting Author: Nitya Ramadoss, PhD

Date/Time: Saturday, October 14, from 12:30 p.m. – 4:00 p.m. PDT

Session Location: Level 2, Exhibit Hall D